Kaletra: Therapy With Double Protease Inhibitors

Study Identifier
P05-103
CT.gov Identifier
NCT01075191
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Human Immunodeficiency Virus (HIV)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Participants with Human Immunodeficiency Virus infection * Participants on lopinavir/ritonavir (Kaletra) and one other protease inhibitor
    Exclusion Criteria:
    * Hypersensitivity against lopinavir, ritonavir or other ingredients * Severe liver insufficiency * No concomitant astemizole, terfenadine, oral midazolam, triazolam, cisapride, pimozide, amiodarone, ergotamine, dihydroergotamine, ergometrine, methylergometrine, vardenafil and St. John's wort

    Protocol Summary

    Therapy with lopinavir/ritonavir (Kaletra) and one other protease inhibitor in Human Immunodeficiency Virus participants

    Study Locations

    Location
    Status
    Location
    Site Reference ID/Investigator# 48283
    Berlin, Germany, 10439
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 28131
    Berlin, Germany, 10551
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 66422
    Berlin, Germany, 10961
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 28123
    Berlin, Germany, 13347
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 28109
    Berlin, Germany, D-10243
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 28115
    Dortmund, Germany, 44137
    Status
    Not applicable
    Showing {first} - {last} of {total} Results